semaglutide pill form over the counter U.S. Food and Drug Administration approved Novo Nordisk's oral (Wegovy) as the first GLP-1 for obesity and cardiovascular risk reduction, with the company targeting an early 2026 launch. Novo Oral Semaglutide for Weight Loss

362 Considering the expression of the GLP-1R in thyroid C cells and the ability of GLP-1 to stimulate calcitonin secretion through a cAMP-mediated mechanism in vitro, it is plausible that calcitonin plays a role in the alterations in bone metabolism observed in GLP-1R-treated animals

Manageable with dose escalation

Both products carry a boxed warning for medullary thyroid carcinoma (MTC) and are contraindicated with MEN2 or a personal/family history of MTC

Some patients prefer to start the regimen on a weekend for maximum appetite suppression, including less craving & food noise

Accelerates weight loss effectively Helps in managing blood sugar levels Can reduce the risk of type 2 diabetes (T2D) Convenient administration through injections or sublingual tablets Supports sustainable weight loss Reduces cravings and appetite Improves overall health and well-being Offers personalized dosage options for individual needs May lead to improved cardiovascular health, and reduced risk of heart attack and stroke